Trial Profile
A Randomized, Double-Blind, Phase 2b Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs AGS 004 (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Sponsors Argos Therapeutics Inc
- 08 Jan 2016 Status changed from active, no longer recruiting to completed according to results published in the JAIDS.
- 08 Jan 2016 Results published in the JAIDS
- 20 Mar 2015 Results will be presented at the HIV Vaccines meeting, part of the Keystone Symposia Global Health Series, in March 2015, according to an Argos Therapeutics media release.